Skip to main content
Equibles
VNDA logo

VNDA · Vanda Pharmaceuticals Inc.

Track VNDA — free

Use VNDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.09 +0.05 (+0.99%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$307.76M
Shares
60.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.09 Open$5.10 Day$5.05–5.17 52W close$4.32–9.56 Avg vol 30d915K Short int7.7M · 12.7% float · 9.9d Short vol43% Last earningsAug 5, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 8 wks
Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$215.72M
Trailing 12 months
Net income (TTM)
−$274.85M
Trailing 12 months
Revenue growth YoY
-3.9%
Year over year
Operating margin
-86.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-46.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$55.88M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+12.5%
Trailing year
Short interest
12.7%
Latest settlement · 9.9 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Vanda reported strong Fanapt growth (Q2 sales up 23% YoY, TRx up 31%) but HETLIOZ sales fell 66% on generic competition, and net loss widened to $62.5M; the company reiterated its 2026 total revenue guidance of $240–$290M and expects operating expenses to begin moderating by year-end 2026 with cash runway through end of 2027.

Bullish
  • + Management reiterated 2026 total revenue guidance of $240–$290M, implying ~23% growth over 2025.
  • + BYSANTI was FDA-approved for bipolar I disorder and schizophrenia with launch expected in 2H 2026.
  • + Quimilza BLA has a December 12, 2026 PDUFA date and was recommended for orphan drug designation by the EU EMA.
Bearish
  • − HETLIOZ Q2 net product sales fell 66% YoY to $5.6M due to generic competition.
  • − NEREUS launch produced only $1M of recognized Q2 revenue with $12.6M constrained amid elevated wholesaler inventory.
  • − Q2 total revenue declined 4% YoY to $50.5M and excludes ~$7M of HETLIOZ orders that will shift to Q3.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −6%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 15%
near low
Momentum
relative strength
Very Weak
1-month return +1%
trailing
6-month return −29%
trailing
YTD return −42%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.71% of float · ▲ +0.2% MoM · 9.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
172 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth +9%
Y/Y
EPS growth −1033%
Y/Y
Free cash flow $-110.4M
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −48%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
Total revenues · Full Year 2026 Initiated $240M – $290M
prior FY $216.11M midpoint +22.6% Y/Y
Fanapt® and BYSANTI™ net product sales · Full Year 2026 Initiated $150M – $170M
Other net product sales · Full Year 2026 Initiated $80M – $90M
Fanapt® and BYSANTITM net product sales · Full Year 2026 Initiated $150M – $170M
NEREUSTM net product sales · Full Year 2026 Initiated $10M – $30M
Prior guidance period ended · from the 8-K filed Jul 31, 2024
Total revenues · Full Year 2024 $180M – $210M
Year-end 2024 Cash · Full Year 2024 $360M – $390M
Guided vs delivered · last 1 settled
Total revenues Full Year 2024
guided $180M – $210M
$198.77M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
15% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.71% of float · ▲ +0.2% MoM · 9.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
172 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $5 · 15% Range high $10
vs 200-day avg -23% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VNDA
Vanda Pharmaceuticals Inc.
this stock
$307.76M -42.3% +8.7% — 12.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
172
% held
82.5%
Net QoQ
+3.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
196
View
Short & Settlement
Short Interest Rising
Shares short
7.7M
Days to cover
9.9d
Change
+17.6K sh
View
Short Volume
Short vol %
43%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
87
Value
$452
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
44.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$216.1M
Net income (FY)
$-220.5M
EPS diluted
$-3.74
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 6, 2026
This year
15
View
Proposed Sales
Value
$254.6K
Shares
30.8K
Filed
Mar 2, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
VNDA -4.7% +1.2% -28.5% -5.7% -42.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -3.5% +2.9% -46.4% -5.4% -54.4%
Key facts CIK 1347178 CUSIP 921659108 13F (30d) 87 filings 87 filers Visit website Investor relations